ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

RB. Reckitt Benckiser Group Plc

6,498.00
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Reckitt Benckiser Group Plc LSE:RB. London Ordinary Share GB00B24CGK77 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 6,498.00 6,502.00 6,506.00 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Reckitt Benckiser Group PLC Offer Talks Terminated

22/03/2018 7:31am

Dow Jones News


Reckitt Benckiser (LSE:RB.)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Reckitt Benckiser Charts.

TIDMRB. TIDMIRSH

RNS Number : 5259I

Reckitt Benckiser Group PLC

22 March 2018

End of discussions for parts of Pfizer's Consumer Health business

21 March, 2018 - Slough, UK - Reckitt Benckiser Group plc ("RB") today announces that it has ended discussions with Pfizer Inc. regarding its Consumer Healthcare business. RB's proposal was for part of the business only.

Rakesh Kapoor, RB CEO, said:

"Our priority remains organic growth, including the completion of the integration of Mead Johnson Nutrition and creating further value from reorganising into two new business units - Health and Hygiene Home.

We always approach inorganic growth opportunities in a rigorous, disciplined, and financially responsible manner to ensure long term value creation for shareholders. An acquisition for the whole Pfizer consumer health business did not fit our acquisition criteria and an acquisition of part of the business was not possible."

-ENDS-

For further information, please contact:

Reckitt Benckiser +44 (0)1753 217800

Richard Joyce

SVP, Investor Relations

Patty O'Hayer

Director, External Relations and Government Affairs

Finsbury (Financial PR) +44 207 251 3801

Faeth Birch / Adam Atashzai

About RB

RB is the global leading consumer health and hygiene company. Driven by a purpose of providing innovative solutions for healthier lives and happier homes, RB has operations in over 60 countries. From the foundations of wellness and infant nutrition, to the fundamentals of a hygienic home, its global brands help people live healthier, happier lives. RB has world leading Powerbrands which include household names such as Enfamil, Nutramigen, Nurofen, Strepsils, Gaviscon, Mucinex, Durex, Scholl, Clearasil, Lysol, Dettol, Veet, Harpic, Cillit Bang, Mortein, Finish, Vanish, Calgon, Woolite and Air Wick. RB's unique culture is at the heart of its success. Its drive to achieve, passion to outperform and commitment to quality and scientific excellence are manifested in the work of over 40,000 employees worldwide. RB is proud to lead the Save a Child a Minute campaign, which aims to eliminate child deaths from diarrhoea, one of the world's largest killers of children under five.

The announcement contains inside information. The person responsible for arranging the release of this announcement on behalf of RB is Rupert Bondy, General Counsel and Company Secretary.

This information is provided by RNS

The company news service from the London Stock Exchange

END

OTTFKDDKKBKBCNB

(END) Dow Jones Newswires

March 22, 2018 03:16 ET (07:16 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.

1 Year Reckitt Benckiser Chart

1 Year Reckitt Benckiser Chart

1 Month Reckitt Benckiser Chart

1 Month Reckitt Benckiser Chart

Your Recent History

Delayed Upgrade Clock